Ashwagandha Supplements Under Fire as Safety Risks Outweigh Unproven Benefits

Ashwagandha supplements remain popular despite growing safety concerns. Marketed for stress relief and metabolism support, these products face scrutiny over unproven benefits and potential health risks. European regulators now advise caution, particularly for vulnerable groups like pregnant women and children. In Germany, ashwagandha supplements are sold as dietary aids without the strict testing required for pharmaceuticals. A 2026 market review revealed many products exceeded Polish dosage guidelines, with one brand offering 6,000 mg of ashwagandha and 15 mg of withanolides daily. Experts note that Germany lacks binding limits, leaving consumers reliant on Poland’s recommended thresholds of 10 mg of withanolides or 3,000 mg of ashwagandha per day.

Label accuracy is another issue. German regulations allow supplement contents to differ by up to 50 percent from what’s listed on packaging. This inconsistency adds to concerns about overdosing, as higher amounts increase the risk of side effects like nausea, dizziness, and liver damage. The Netherlands has reported 12 cases of liver damage linked to ashwagandha use. While small studies suggest benefits for stress and sleep at doses of 600 mg over eight weeks, broader claims—such as lowering cortisol or boosting metabolism—lack strong scientific backing. Withanolides, the plant’s active compounds, have shown anti-tumor effects in lab tests but have not been studied in human trials. European authorities now warn against ashwagandha use due to insufficient safety data. They urge pregnant women, breastfeeding mothers, and children to avoid it entirely, citing potential risks that outweigh unproven benefits.

Ashwagandha supplements continue to be sold with limited oversight in Germany. Without strict dosage controls or proven efficacy, consumers face uncertainty about both safety and effectiveness. The reported cases of liver damage and inconsistent product labelling highlight the need for clearer regulations and further research.